- Home
- BFRG vs PHIO Comparison
BFRG vs PHIO Comparison
Compare BFRG & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRG | PHIO |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 12.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | BFRG | PHIO |
|---|---|---|
| Price | $1.12 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 68.3K | ★ 360.2K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,670.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.97 |
| 52 Week High | $4.84 | $9.79 |
Technical Indicators
Market Signals| Indicator | BFRG | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.78 | 31.72 |
| Support Level | $0.98 | $1.04 |
| Resistance Level | $1.21 | $1.20 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.71 | 10.35 |
Price Performance
Historical ComparisonAbout BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.